Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PST 611

Next Previous
X
Search
Drug Profile

PST 611

Alternative Names: EYS-611; PST-611

Latest Information Update: 12 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eyevensys
  • Developer PulseSight Therapeutics
  • Class Antiglaucomas; Eye disorder therapies; Gene therapies; Neuroprotectants
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dry macular degeneration; Glaucoma; Retinitis pigmentosa

Most Recent Events

  • 06 Nov 2024 PulseSight Therapeutics plans to submit CTA for Dry macular degeneration, by the end of 2024
  • 07 Oct 2024 PulseSight Therapeutics plans a phase II proof-of-concept trial by end 2027
  • 02 Sep 2024 Pulsesight Therapeutics plans a clinical trial for Dry macular degeneration by the end of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top